Browse the corpus

Genital warts (condyloma acuminata) represent the visible manifestation of infection with low-risk human papillomavirus types, most commonly HPV-6 and HPV-11, which account for about 90% of cases. This course reviews the wide range of presentations that clinicians may encounter, from small solitary lesions to extensive clusters involving the anogenital region. The diagnostic evaluation of condyloma acuminata, which relies primarily on visual inspection and is supported by biopsy when features suggest malignancy, when lesions are pigmented or ulcerated, or when the patient is immunocompromised, is also discussed. Additionally, this activity outlines the natural history of HPV, the limitations of diagnostic tools, such as the acetowhite effect, and the benefits and drawbacks of topical, ablative, and adjunctive therapies, as well as treatment selection and counseling. Participants will also gain a clearer understanding of HPV transmission dynamics, varied clinical presentations, and recurrence patterns. This activity for healthcare professionals is designed to enhance the learner's competence in identifying genital warts, selecting appropriate topical or surgical interventions, recognizing red-flag findings, coordinating sexually transmitted infection screening, guiding patients on expectations, precautions, and follow-up care, and implementing an appropriate interprofessional approach to manage this condition to improve patient outcomes. Objectives: Identify the etiology of condyloma acuminata. Determine biopsy indications for the evaluation of condyloma acuminata. Evaluate the use of physically destructive therapies in the management of genital warts. Collaborate with interprofessional team members to improve collaboration of care and outcomes in patients with genital warts. Access free multiple choice questions on this topic.

Genital warts (condyloma acuminata) are the clinical manifestations of a sexually transmitted infection (STI) caused by some types of human papillomavirus (HPV).[1] Genital warts are a recognized symptom of genital HPV infections. About 90% of those exposed who contract HPV will not develop genital warts, and only about 10% who are infected will transmit the virus. Two types, HPV types 6 and 11, cause 90% of all genital warts.[2][3][4] The American Cancer Society reports that there are over 200 different known types of HPV, but only 14 are considered high-risk for possible malignant transformation, including anal, cervical, oropharyngeal, and penile cancers.[2][5][6][7][8][9][10][11] Human papillomavirus is spread through direct skin-to-skin contact with an infected individual, usually during sex.[2][3] While some types of HPV cause cervical and anal cancer, these are not the same viral types that cause genital warts (see Image. Condylomata Acuminata).[12][13] Infection with different HPV types at the same time is also possible.[1]

Human papillomavirus, including HPV types 6 and 11, which cause 90% of condyloma acuminata, is transmitted primarily through penetrative sex and less commonly through direct skin contact involving the anogenital area.[1][2][14]

Genital HPV infections have an estimated prevalence of 10% to 20%, with clinical manifestations (genital warts) in 1%.[2][15] The incidence of HPV infection has been increasing, with over 90% of sexually active men and 80% of sexually active women infected with HPV in their lifetime, and 80% of sexually active men and women becoming infected by age 45.[16][17] About 80% of those infected are between 17 and 33 years old, with the peak age group being 20 to 24.[16] The overall prevalence of genital HPV infections in men aged 14 to 59 in the United States was 42.2%, with a prevalence of 45.2% for men aged 18 to 59.[18][19] The Centers for Disease Control (CDC) has estimated that 13 million new HPV infections are diagnosed annually in the United States, with over 42 million Americans already infected. The male-to-female ratio is about 1:1.[20] Older data indicated that genital warts are about twice as common in Caucasians as in African or Asian Americans, but more recent studies show that Black adults have the greatest incidence of high-risk genital HPV infections.[21][22][23][24] Intraepidermal carcinoma (Bowen disease) of the penis, and about 35% to 40% of all penile cancers are associated with HPV infections.[25][26] Please see StatPearls' companion resource, "Intraepidermal Carcinoma," for further information. The median age for clearing of HPV infections in young men (16 to 24 years) is about 6 months, while in women, 90% will clear the infection in 2 years.[27][28] Although treatments can remove warts, they do not remove HPV. Warts often regress spontaneously, but this is not guaranteed, and the process is slow as the body's immune system clears the virus. This often takes months or years, with about 65% of genital warts resolving on their own after 2 years without sequelae or scarring.[29][30][31] Traditional theories hold that the virus remains in the body for life. However, experts now believe that the virus may be cleared or suppressed to levels below the detection limit of polymerase chain reaction (PCR) tests.[32][33][34][35][36]

Although treatments can remove warts, they do not remove HPV. Warts often regress spontaneously, but this is not guaranteed, and the process is slow as the body's immune system clears the virus. This often takes months or years, with about 65% of genital warts resolving on their own after 2 years without sequelae or scarring.[29][30][31] Traditional theories hold that the virus remains in the body for life. However, experts now believe that the virus may be cleared or suppressed to levels below the detection limit of polymerase chain reaction (PCR) tests.[32][33][34][35][36] HPV infection appears to be the cause of most cases of anal cancer (about 90%) and virtually all cases of cervical cancer in women, with HPV type 16 accounting for about 50% of these (cervical cancer is the fourth most common cancer in women).[37] Some vulvar cancers have been linked to HPV infections (29% to 43%), while vaginal cancer is associated with HPV infections about 70% of the time (HPV Types 16 and 18).[38] Risk factors for HPV infections and their persistence include the following: Age Age at first exposure to HPV Early sexual activity (particularly before 18 years) Failure to use sexual contact protection Genetic factors (polymorphisms in the human leukocyte antigen (HLA) system) Immunosuppressive state Increased cytokines like interleukin (IL-10, IL-6), and transforming growth factor (TGF-β1) Lack of HPV vaccination (especially among young men, whose vaccination rates are particularly low) Micronutrient deficiencies (beta-carotene, lutein, lycopene, tocopherols, vitamins C and E) Multiple sexual partners Simultaneous infection with multiple HPV types, HIV, or other STIs Smoking Use of oral contraceptives Viral factors and HPV type [39][40][41][42][43][44][45][46][47][48][49][50][51] HPV Vaccinations An HPV vaccination is available and recommended by the CDC for high-risk groups, particularly sexually active adolescents and young adults.[52][53] Recommendations include: For previously unvaccinated adults, the CDC recommends vaccination for those aged 27 to 45. For adolescents, the CDC recommends the vaccine be given at ages 11 or 12, but it may be started as early as 9.

The neoplastic mechanism of genital wart development involves the human papillomavirus (types 6 or 11) entering basal epithelial cells and using specific viral proteins to manipulate the host cell's growth cycle, leading to the formation of a benign tumor or wart. Fortunately, the HPV types (6 and 11) that cause 90% of anogenital warts have a low risk of malignant transformation.[2][3][4] The process is described in more detail as follows: Viral entry occurs via microscopic skin cuts, ulcers, or abrasions, allowing viral access to metabolically active, rapidly replicating basal epithelial cells (keratinocytes). Initial contact with the basement membrane is facilitated by the major HPV capsid protein L1 binding to host heparan sulfate proteoglycans.[54] HPV entry into cells involves interactions between viral capsid proteins and proteases, as well as with various cellular receptors, ultimately leading to endocytosis and cellular internalization.[54] After cellular entry, the virus first localizes in the endosomal system, the endoplasmic reticulum, and the Golgi complex en route to the nucleus.[54] Once in the nucleus, the HPV genome becomes an extrachromosomal episome, protecting the virus from the immune response while enabling viral replication and spread via daughter cells.[54] As infected cells migrate to the surface and begin to differentiate, cellular replication would normally stop.[54] However, the virus produces specific proteins, eg, E6 and E7, that allow cellular growth to continue.[54] Tumor suppressor proteins p53 and pRb are strongly inactivated by high-risk HPV types, but not by the low-risk HPV types (HPV types 6 and 11) typically associated with genital warts.[2][3][4] These factors, taken together, keep infected cells in a constant, uninhibited proliferative state, leading to unchecked cellular growth and ultimately to the characteristic skin thickening, localized neoplastic enlargement, and protrusion of a genital wart. The body's natural immune system can often clear the virus, but if this fails, recurrences are likely even after successful treatment with apparent wart clearance.

Genital warts are typically diagnosed visually, with a confirmatory biopsy generally being unnecessary. The exophytic lesions result from enlargement of the dermal papillae and are lined by hyperplastic squamous epithelium that shows koilocytes, squamous epithelial cells characterized by an acentric, hyperchromatic nucleus displaced by a large perinuclear vacuole.[55] Patients with long-duration HPV infections, particularly with HPV types 16 and 18, are at risk for possible cancerous transformation of their HPV-associated lesions.[3][56][57][58][59][60]

Condylomata acuminata may occur separately or in clusters. They may be found in the anal or genital area, including the penile shaft, scrotum, vagina, or labia majora, as well as on the internal surfaces of the vagina and the anus (see Images. Female Genital Warts and Male Genital Warts).[3][61] Genital warts can be small (5 mm or less in diameter) or spread into large masses in the genital or anal areas, which is the common finding.[3] The color of these lesions varies from skin-colored to darker, and they may occasionally bleed spontaneously.[3] The appearance of genital warts depends on the site of infection, host factors, viral load, and the specific HPV type involved.[3][56] In most cases, the only identifiable sign or symptom of an HPV infection is genital warts. Sometimes, condylomata acuminata may cause itching, redness, a burning sensation, increased moisture in the genital area, an unusual vaginal discharge, or discomfort, and they may also result in psychological distress.[3] Oropharyngeal involvement may cause additional symptoms, such as a persistent sore throat, chronic cough, hoarseness, pain on chewing, enlarged lymph glands, white or reddish tonsillar lesions, or an earache. Clinical Signs of Malignancy Signs of possible malignancy include the following: Bleeding Flat blueish-brown neoplasms Irregular pigmentation Nonhealing ulcer Palpable evidence of dermal infiltration Penile rash Small, crusty bumps [3][26][62]

The diagnosis of condylomata acuminata is primarily made clinically, although a biopsy may be necessary for confirmation (see Image. Labial Condyloma Acuminata). Small warts may sometimes be confused with molluscum contagiosum. Genital warts typically rise above the skin surface, have parakeratosis, and demonstrate nuclear changes typical of HPV infections (nuclear enlargement with perinuclear clearing).[3] Because low-risk HPV types cause genital warts, DNA tests should not generally be used for diagnosis or in low-risk HPV infections. All patients with genital warts should be screened for STIs.[62] The "acetowhite" effect is produced when a dilute 3% to 5% acetic acid (vinegar) solution is applied to the skin with a moistened gauze pad for 5 to 10 minutes, causing cells infected with HPV to turn white.[63][64][65] Acetic acid causes coagulation of intracellular proteins in cells with a high nuclear-to-cytoplasmic ratio, eg, those infected with HPV, those with psoriasis or candidiasis, and patients with precancerous or malignant lesions, which then appear opaque white.[63][64] While useful and sensitive in detecting even subclinical HPV skin infections, acetic acid is not very specific and can sometimes be misleading, with many false positives. Therefore, this test is not recommended for routine screening, and a biopsy may be needed for a definitive determination. The acetowhite effect can also be used as a cost-effective method of initial screening for cervical cancer in areas with limited medical resources, but this test is less sensitive and not as reliable as HPV DNA testing, which is preferred.[66][67][68] Biopsies are recommended if clinicians are uncertain about the diagnosis or if the patient is immunocompromised.[69] Pigmented and ulcerated lesions should also be considered for biopsy.[3] Moreover, cystoscopy should be considered in patients with glans involvement, lower urinary tract symptoms, or significant urethral symptoms. In patients who have no symptoms, some experts have suggested waiting until any glans lesions have healed to avoid possible transfer of the HPV virus into the urethra.[70][71]

No known cure for HPV has been developed. Furthermore, removing visible warts does not necessarily reduce the transmission of the underlying HPV infection.[72][73][74] About 80% of individuals with HPV will clear the infection spontaneously within 18 to 24 months.[51][75][76] The American Urological Association does not recommend treating subclinical (invisible) lesions. Factors that negatively affect the spontaneous clearance of HPV include a higher number of sexual partners, genetic factors, smoking, immunosuppression, coinfection with other STIs (eg, HIV, herpes simplex, Chlamydia trachomatis), multiparity, and longer use of oral contraceptives in women.[51][77][78][79][80][81] Treatment of condyloma acuminata varies depending on the number, size, and location of warts. Additionally, treatment can cause permanent depigmentation, itching, pain, and scarring. Urethral meatus warts are best treated with surgery to minimize long-term complications. Treatments are either ablative (eg, vaporization, resection, coagulation, or excision) or topical agents.[3] Physically ablative treatments are more effective for wart removal, but in many cases, patients prefer topical agents as initial therapy, especially for smaller lesions. Topical Therapies and Oral Agents Topical agents may be very effective, self-applied by patients, and less traumatic than surgical intervention. However, patient compliance is spotty, and recurrences are common. Imiquimod Imiquimod is a topical immune response cream applied to the affected area, but it may cause fungal infections and flu-like symptoms. Imiquimod is an immune enhancer that increases cytokine production (eg, tumor necrosis factor alpha (TNF-α), interleukin 6 (IL-6), and interferon alpha).[82][83][84][85][86][87] This enhances a cytotoxic T-cell-mediated immune response.[85][88] Wart recurrence rates are lower than with podophyllin-based therapies, and imiquimod tends to result in healing without scarring.[89]

Imiquimod is a topical immune response cream applied to the affected area, but it may cause fungal infections and flu-like symptoms. Imiquimod is an immune enhancer that increases cytokine production (eg, tumor necrosis factor alpha (TNF-α), interleukin 6 (IL-6), and interferon alpha).[82][83][84][85][86][87] This enhances a cytotoxic T-cell-mediated immune response.[85][88] Wart recurrence rates are lower than with podophyllin-based therapies, and imiquimod tends to result in healing without scarring.[89] The recommended application schedule for imiquimod 5% cream is 3 times per week.[90] The use of imiquimod 3.75% cream has been recommended as being equally effective while minimizing local adverse effects such as pain, burning, inflammation, itching, and erythema.[91][92][93] Usage may also be limited by cost, as the medication is relatively expensive if not covered by insurance. Imiquimod topical therapy is often effective when used adjunctively after ablative or surgical treatment.[86] It has a reported clearance rate of 35% to 68% with a recurrence rate of 6% to 26%.[3][62] Isotretinoin Isotretinoin is an oral medication typically used for acne, which is also available as a topical gel, though oral administration is more effective.[94] This medication reduces sebum production, shrinks sebaceous glands, exerts an anti-inflammatory effect, and has antibacterial benefits. Isotretinoin is generally reserved for recalcitrant, extensive, or intractable genital warts.[95] Isotretinoin has also shown significant efficacy when used as an adjunct to standard treatment for genital warts in immunocompromised patients, particularly when the condyloma is extensive or the lesions have proven resistant to initial therapy.[62][94][95][96][97][98] Isotretinoin therapy is most effective when combined with other genital wart treatments, including surgical debulking, cryotherapy, interferon-alfa-2a, and topical imiquimod.[98][99][100] The standard or higher dosage protocol is 0.5 to 1 mg/kg/day, but a low-dose schedule of 0.3 mg/kg/day has also been used, albeit with a lower genital wart clearance rate. Standard topical therapy is continued during oral isotretinoin treatment.

Isotretinoin therapy is most effective when combined with other genital wart treatments, including surgical debulking, cryotherapy, interferon-alfa-2a, and topical imiquimod.[98][99][100] The standard or higher dosage protocol is 0.5 to 1 mg/kg/day, but a low-dose schedule of 0.3 mg/kg/day has also been used, albeit with a lower genital wart clearance rate. Standard topical therapy is continued during oral isotretinoin treatment. Many potential adverse effects are associated with isotretinoin therapy, so it must be used cautiously. In particular, isotretinoin can cause very severe birth defects and should absolutely not be used in pregnancy.[101][102][103][104] For women of childbearing age, this means 2 pregnancy tests initially and monthly while on medication. They must also use 2 separate forms of birth control. Adverse effects include dry skin, chapped lips, frequent nosebleeds, dry eyes, dry mouth, and severe sun sensitivity while on the medication. Additionally, night blindness, hair thinning, muscle aches, arthralgias, rashes, stomach problems, and higher cholesterol levels may occur. Liver damage, urethritis, and hydrocephalus have been reported but are quite rare.[105] Adverse effects are typically dose-dependent. A few reported cases of severe depression and suicide are associated with the use of isotretinoin, as well as possibly exacerbation of inflammatory bowel disease. For these reasons, isotretinoin is dosed at 30-day intervals and should be used cautiously.[96] Higher-dose isotretinoin therapy has a genital wart clearance rate of about 56% to 76%, while the lower-dose treatment schedules have a lower reported clearance rate of approximately 35% to 45%.[106][107] Overall recurrence risk is about 12%, with lower rates (7.8%) observed with higher isotretinoin dosage schedules.[94][95][106][108] Recurrence rates with the lower-dose schedule are higher at 26%.[106] Podophyllotoxin

Higher-dose isotretinoin therapy has a genital wart clearance rate of about 56% to 76%, while the lower-dose treatment schedules have a lower reported clearance rate of approximately 35% to 45%.[106][107] Overall recurrence risk is about 12%, with lower rates (7.8%) observed with higher isotretinoin dosage schedules.[94][95][106][108] Recurrence rates with the lower-dose schedule are higher at 26%.[106] Podophyllotoxin A 0.15% to 0.5% podophyllotoxin solution in a gel or cream can be applied to the affected area and is not washed off. Podofilox (an anti-mitotic drug) appears to be safer than podophyllin.[109] It works by binding microtubular subunits.[88] A recent meta-analysis concluded that podophyllotoxin-related therapies are overall the most effective.[86] The gel form is easier for patients to apply than the liquid with equal efficacy.[110] The recommended application schedule (apply BID for 3 days, then 4 days off, then repeat) can be confusing for some patients. Adverse effects include localized burning, itching, pain, and inflammation. Podophyllotoxin-related therapies should not be used in pregnancy. The original precursor topical therapy, podophyllin, is no longer recommended by the CDC due to its high level of mutagens.[111] The reported clearance rate for podophyllotoxin-based topical therapy ranges from 45% to 83%, with a highly variable recurrence rate of up to 100%.[3][62] Sinecatechins Sinecatechins are an ointment of catechins extracted from green tea that appear to have a higher wart clearance rate than podophyllotoxin and imiquimod, while causing less local irritation, but clearance takes longer than with imiquimod. The overall genital wart clearance rate is reported to be 47% to 59%, with a recurrence rate of only 7% to 11%.[3][62][112] Sinecatechins are available as a 15% ointment. The exact mechanism of action is unknown, but they have immunostimulatory, anti-proliferative, and anti-tumor properties and appear to work by reducing the expression of HPV gene products E6 and E7.[113] Adverse effects include local redness, inflammation, and pain. Trichloroacetic acid

Sinecatechins are available as a 15% ointment. The exact mechanism of action is unknown, but they have immunostimulatory, anti-proliferative, and anti-tumor properties and appear to work by reducing the expression of HPV gene products E6 and E7.[113] Adverse effects include local redness, inflammation, and pain. Trichloroacetic acid Trichloroacetic acid is not as effective as cryosurgery and should be avoided on the vagina, cervix, or urinary meatus.[55] This medication has a high recurrence rate and should be applied only by a healthcare practitioner due to the potential for injury to surrounding tissues.[114] Skin erosion and pain are most commonly reported with imiquimod and sinecatechins. The clearance rate for trichloroacetic acid topical therapy is 56% to 81% with a recurrence rate of 36%.[3][62] Physical (Surgical) Removal or Destruction Direct surgical excision or physically destructive therapies are considered more effective for keratinized warts, especially when they are more extensive[55] Cryotherapy Cryotherapy with liquid nitrogen is inexpensive, considered safe for use during pregnancy, and does not usually cause much scarring, but requires cryosurgical equipment and training. It may require anesthesia due to pain, and multiple treatments are often necessary. The reported genital wart clearance rate ranges from 44% to 75% with a recurrence rate of 21% to 42%.[3][62] Electrocauterization Electrocauterization is considered adequate but causes scarring and requires some level of anesthesia.[55] Laser vaporization Laser vaporization with a CO2 laser has minimal bleeding but may be somewhat less effective than other ablative techniques. It is typically used for extensive areas of genital wart involvement, but it is relatively expensive and may cause a plume of virus-containing smoke.[115][116] Photodynamic therapy

Electrocauterization is considered adequate but causes scarring and requires some level of anesthesia.[55] Laser vaporization Laser vaporization with a CO2 laser has minimal bleeding but may be somewhat less effective than other ablative techniques. It is typically used for extensive areas of genital wart involvement, but it is relatively expensive and may cause a plume of virus-containing smoke.[115][116] Photodynamic therapy Photodynamic therapy with a photosensitizing agent (eg, aminolevulinic acid) has demonstrated efficacy in eliminating external genital warts.[117][118] The aminolevulinic acid is applied topically or directly intralesionally. The photosensitizing agent is quickly absorbed by the fastest-growing cells. Light exposure activates aminolevulinic acid, releasing free oxygen singlet radicals that directly destroy the wart by oxidative injury.[119][120][121][122] Photodynamic therapy has also been used successfully for genital warts in the pediatric age group and may be the single most effective treatment for urethral warts, albeit with a relatively high risk of complications.[121][123][124] Photodynamic therapy for genital warts is currently considered off-label. However, this treatment is generally more effective, simpler, and has lower recurrence rates than CO2 laser therapy alone.[3][125] The reported genital wart clearance rate with phodynamic therapy ranges from about 63% to over 98%, with higher rates often requiring multiple sessions, while recurrence rates average about 17%.[126] Surgical excision Simple surgical excision under local anesthesia is simple and direct, but it will leave a scar and require a small surgical procedure.[72] Surgical removal under general anesthesia may be necessary for more extensive lesions, intra-anal warts, or in children. Therapies No Longer Routinely Recommended Therapies that are no longer recommended as standardized treatments include: Fluorouracil (5-FU) 5% cream is no longer considered an acceptable initial first-line therapy for genital warts due to adverse effects (pain, irritation, peeling of skin), questionable efficacy due to poor study quality, and the availability of multiple superior agents.[127] Interferon intralesional injections initially showed moderate efficacy, with a complete response rate of 36% to 63% as monotherapy, but other treatments have largely supplanted it.[91]

Fluorouracil (5-FU) 5% cream is no longer considered an acceptable initial first-line therapy for genital warts due to adverse effects (pain, irritation, peeling of skin), questionable efficacy due to poor study quality, and the availability of multiple superior agents.[127] Interferon intralesional injections initially showed moderate efficacy, with a complete response rate of 36% to 63% as monotherapy, but other treatments have largely supplanted it.[91] Interferon might still be considered for intractable cases as an adjunctive therapy.[91] Podophyllin, podofilox, and especially isotretinoin should be avoided during pregnancy.[128][129]

Differential diagnoses that should be considered when evaluating patients for suspected condyloma acuminata include: Acrochordon [130] Benign familial pemphigus [131] Benign nevi [132] Buschke-Lowenstein tumor [133][134] Condyloma lata or secondary syphilis[135] Herpes simplex infection[136][137] Lichen planus[138] Malignancy (anal, cervical, oropharyngeal, penile, vulvar) [26][139][140][141][142][143] Molluscum contagiosum [144] Pearly penile papules [145] Penile cancer[26] Penile intraepithelial neoplasia [26] Psoriasis [146] Sebaceous cysts [147] Sexually transmitted diseases: Herpes simplex virus (HSV): Small, painful blisters that progress to ulcers and sores.[136][137] Chancroid: Causes painful, soft-edged ulcers with soft edges.[148] Granuloma inguinale (donovanosis): An infection that causes beefy-red, open sores.[149] Lymphogranuloma venereum: A bacterial infection that starts as a small, painless sore.[150]Syphilis: This STI causes a single, painless ulcer (chancre).[151][152][135] Skin tags [153] Vulvar neurofibromatosis [154]

A large number of cases of condyloma acuminata fail to respond to treatment and often recur, especially with repeated infections from sexual contact or the long incubation period of HPV. Verifying patient compliance with therapy, changing the therapeutic agent, and adding isotretinoin can help. Morbidity associated with the disease is due to pruritus, bleeding, and the psychosocial burden of genital lesions, while mortality is due to its malignant transformation to squamous cell carcinoma. Immunocompromised patients are likely to have more resistant lesions and more frequent recurrences than the general population. They are also more likely to develop malignant transformation into squamous cell carcinoma.[155][156] In general, immunocompromised patients benefit from a combination of therapies, early addition of isotretinoin, longer treatment duration, and earlier surgical intervention.[157]

Local complications with disfigurement are the most common complications of condyloma acuminata. With untreated and advanced-stage disease, a risk of malignant transformation is present, which is the most feared complication. Buschke-Lowenstein tumors are a known complication of genital warts.[133][134] The current standard of care emphasizes treatment and primary prevention strategies, including vaccination, to prevent this devastating outcome.

Gardasil is a vaccine that protects against human papillomavirus types 6, 11, 16, and 18. HPV types 16 and 18 cause an estimated 70% of all cervical cancers, and types 6 and 11 cause an estimated 90% of genital warts. The vaccine prevents the disease but is not therapeutic and must be given before exposure to the virus type to be effective.[53] The vaccine was approved by the United States Food and Drug Administration (FDA) in 2006 for use in children as young as 9 years old, primarily for its prophylactic activity against cervical cancer.[53][158] Gardasil 9 was FDA-approved in 2014 to protect against the 4 HPV strains covered by the first-generation Gardasil, as well as 5 other HPV strains responsible for 20% of cervical cancers (HPV-31, HPV-33, HPV-45, HPV-52, and HPV-58).[53][158][159] Vaccines are preventative and should not be considered therapeutic. Quadrivalent or 9-valent vaccines are recommended and generally preferred over bivalent vaccines. According to the Advisory Committee on Immunization Practices (ACIP), routine HPV vaccination is recommended for women aged 9 to 26, and it has demonstrated high efficacy through age 45.[53][158] The CDC advises that unvaccinated adults aged 26 to 45 may receive the vaccine after discussing it with their physician.[53][158] The ACIP recommends routine HPV quadrivalent vaccination for males at age 11 to 12.[53][158] If not previously given or incomplete (the vaccine is a 3-dose series), the vaccine should be given through age 21.[53][158] From ages 22 to 26, the vaccine is considered optional.[53][158] In other words, the optimal age for male HPV vaccination is 11 to 12 years, but it may be administered up to age 45. More extensive and widespread use of human papillomavirus vaccines appears able to reduce the prevalence and penetration of HPV infections, complications, genital warts, and HPV-related malignancies.[52][160][161][162][163][164][165][166][167][168][169][170][171]

Factors that should be kept in mind in the management of genital warts include: About 30% of genital warts will disappear within 4 months of their initial appearance.[2] According to the CDC and National Cancer Institute, human papillomavirus types 6 and 11 cause about 90% of genital warts, while HPV types 16 and 18 are associated with most cervical, vaginal, penile, and anal cancers.[2][3][4][26][58][59][139][140][141][172] Although 90% of HPV infections are cleared within 2 years of infection, it is possible for a latency period to occur, with the first occurrence or a recurrence happening months or even years later.[173][174] Anal or genital warts may be transmitted during birth and may be an indicator of sexual abuse.[175][176] Approximately 3 out of 4 unaffected partners of patients with genital warts develop warts within 8 months of contact with the affected individual.[2] Curcumin, a derivative of turmeric, has been reported anecdotally to be effective against genital warts, but further studies are needed to determine its safety and efficacy.[177][178] Experimentally, a nitric acid/zinc complex solution for topical application has been successfully used on difficult-to-treat warts. The solution includes dilute nitric acid, zinc, copper, and organic acids.[179][180] The application of this solution causes destruction and desiccation of the wart through a combination of denaturation and active protein coagulation actions.[179][180] So far, it appears to be well-tolerated and effective.[179][180] Genital warts may sometimes result from autoinoculation by warts elsewhere on the body, eg, from the hands.[181] HPV can remain latent for months or years before progressing to the growth of genital warts.[51] In individuals with a prior HPV infection, the appearance of new warts may be either from a new exposure or a recurrence.[182] Latent HPV without visible warts is transmissible, and if an individual has unprotected sex with an infected partner, there is a 70% chance they will become infected.[183] Most genital warts will recur within 3 months of completion of initial therapy, even if therapy was followed correctly.[2] Recurrence rates depend on the patient's general health and immune status, previous HPV vaccinations, specific HPV strain, number of inoculations (sexual frequency with an infected partner), use of condoms, and the viral load.[182][184]

Most genital warts will recur within 3 months of completion of initial therapy, even if therapy was followed correctly.[2] Recurrence rates depend on the patient's general health and immune status, previous HPV vaccinations, specific HPV strain, number of inoculations (sexual frequency with an infected partner), use of condoms, and the viral load.[182][184] Smoking increases the risk of getting genital warts from HPV.[185][186][187] Condom use is recommended and is generally considered helpful, but it only offers incomplete protection from transmission of HPV and genital warts.[188][189][190][191][192] Topical antivirals, such as cidofovir, appear promising, but further study is needed before they can be safely used clinically.[193][194][195][196] Virus transmission and infection are less likely but may still occur even without any visible genital warts.[3][197]

Genital warts represent a common clinical manifestation of infection with low-risk HPV types, most frequently HPV-6 and HPV-11. Condyloma acuminata lesions may appear singly or in clusters and can involve the genital, anal, or oropharyngeal regions, with presentations influenced by host factors, viral load, and HPV type. Diagnosis relies on visual assessment, with biopsy reserved for atypical, pigmented, ulcerated, or uncertain lesions. Management includes topical, ablative, and adjunctive therapies, yet recurrence remains common. Prevention plays a central role, as quadrivalent HPV vaccination significantly reduces HPV-related infections, genital warts, and associated malignancies. Effective care requires coordinated, interprofessional collaboration among physicians, general practitioners, advanced practitioners, nurses, pharmacists, and allied health professionals. Clinicians must use strong communication skills to educate patients and families on HPV transmission, the natural history of infection, and evidence-based treatment options. A unified strategy ensures timely diagnosis, appropriate therapy selection, and consistent counseling regarding HPV vaccination, which is recommended routinely at age 11 or 12 and permitted starting at age 9, with catch-up vaccination through age 26. Shared decision-making between clinicians and adults aged 27 through 45 supports individualized vaccination choices. Interprofessional coordination strengthens patient-centered care, enhances safety, and improves long-term outcomes.[53]